(1) International Study Group for Behcet’s Disease. Criteria for diagnosis Of Behcet’s disease. Lancet 1990 ; 335 :1078-80
(2) Adnan Al-Araji, Desmond P Kidd. Neurobehcet’s disease: epidemiology, clinical characteristics, and management. Lancet Neurol 2009;8:192-204.
(3) Albayram S1, Saip S, Hasiloglu ZI, Teke M, Ceyhan E, Tutuncu M, Selcuk H, Kina A, SivaA. Evaluation of parenchymal neuro-behçet disease by using susceptibility-weighted imaging. AJNR Am J Neuroradiol. 2011 Jun-Jul;32(6):1050-5.
(4) Tursen U, Gurler A, Boyvat A. Evaluation of clinical findings according to sex in 2003. Int J Dermatol. 2003 May;42(5):346-51.
(5) Farah S, Al-Shubaili A, Montaser A et al. Behcet’sSyndrome : a report of 41 patients with emphasis on neurological manifestations. J NeurolNeurosurg Psychiatry 1998 ; 64 :382-84 .
(6) S. B’chirHamzaoui, A.Harmel, K.Bouslama, M.Adallah et al. La maladie de Behcet en Tunisie. Etude clinique de 519 cas. La Revue de médecine interne 27 (2006) 742–750.
(7) Mohamed-Habib Houman, SyrineBellakhal, Thouraya Ben Salem, AmiraHazaoui et al. Characteristics of neurological manifestations of Behcet’sdisease :A retrospective monocentric study in Tunisia. Clinical Neurology and Neurosurgery 115 (2013) 2015-2018.
(8) Sidhom Y, Maillart E, Tezenas du Montcel S, Kacem I, Lubetzki C, Gouider R, Papeix C. Fast multiple sclerosis progression in NorthAfricans: Bothgenetics and environmentmatter.Neurology. 2017 Mar 28;88(13):1218-1225.
(9) SeemaKalra, Alan Silman, GulsenAkman-Demi et all. Diagnosis and management of Neurobehcet’sdisease : International consensus recommendations.JNeurol (2014)261 : 16662-1676
(10) ShunseiHirohata and Hirotoshi Kikuchi. Changes in Biomarkers Focused on Differences in disease course or treatement in patients with Neurobehcet’s Disease. Inter Med 51 : 3359-3365, 2012
(11) GuherSaruhan-Direskeneli, Sibel P. Yentur, GulseAkman-Demiret all. Cytokines and chemokines in Neurobecet’s Disease compared to multiple sclerosis and other neurological dieases. Journal of Neuroimmunology 145 (2003) 127-134
(12) KamelHamzaoui, AfshinBorhani-Haghighi, WajihKaabach and Agnes Hamzaoui. Increased Interleukine 33 in patients with Neurobehcet’sdisease : correlation with MCP-1 and IP-10 chemokines. Cellular and Molecular Immunology (2014) 11, 613-616
(13) A.BohaniHaghighi, H.IttehadiA.R.Niksereht, J Rahmati, S.GhaffariPoorjahromiet all. CSF levels of cytokines in neuro-Behcet’s disease. Clinical Neurology and Neurosurgery 111 (2009) 507-510
(14) BorhaniHaghighi A, Pourmand R, Nikerseresht. Neurobehcet’sdisease : a review. The Neurologist 2005 ; 11 : 80-9
(15) ShunseiHirohata, Hirotoshi Kikuchi, Tetsuji Sawada, Hiroko Nagafuchiet all. Clinical Characteristics of Neurobehcet’s disease in Jupan : a multicenter retrospective analysis. Mod Rheumatol (2012)22 :405-413
(16) Wang CR, Chuang CY, Chen CY. Anticardiolipin antibodies and interleukine-5 in cerebrospinal fluid and blood of chineese patients with neurobehcet’s syndrome. ClinExpRheumatol1992 ; 10 : 599-602
(17) Akman-Demir G, ErdemTuzun, SemaIcoz et al (2008) Interleukinn-6 in NeuroBehcet’s disease : association with disease subsets and long term outcome. Cytokine 44 :373-376
(18) Hirohata S, Isshi K, Oguchi H et all (1997), cerebrospinal fluid interleukine 6 in progressive neurobehcet’s syndrome. ClinImmunopathol82 :2-17
(19) Al-Araji A, Sharquie K, Al-Rawi Z. Prevalence and patterns of neurological involvement in Behcet’s disease : a prospective study from Iraq. J.NeuroNeurosurg Psychiatry 2003 ; 74 :608-13
(20) Serdaroglu P, Yazici H, Ozdemir C, Yurdakul S, Bahar S, Aktin E. Neurological involvement in Behcet’s disease- A prospective study. Arch Neurol1989 ; 46 : 265-69
(21) Ashjazadeh N, BorhaniiHaghighi A, Samangooie S, Moosavi H. Neurobehcet’s disease : a masquerader of multiple sclerosis. A prospective study of neurologic manifestations of Behcet’s disease in 96 Iranian patients. ExpMolPathol2003 ; 74 : 17-22
(22) Kidd ,Steuer A, Denman AM, Rudge P. Neurological complications of Behcet’s syndrome. Brain 1999 ; 122 : 2183-94
(23) Akman-Demir G, Serdaroglu P, Tasci B. Clinical Patterns of 200 patients. The Neurobehcet study Group. Brain 1999 : 122 : 2171-82
(24) Al-Fahad S, Al-Araji A. Neurobehcet’s disease in Iraq : a study of 40 patients. J NeurolSci1999 ; 170 :105-11
(25) Joseph FG, Scolding NJ. Neurobehcet’s disease in caucasians : a study of 22 patients. Eur J Neurol2007 ; 14 :174-80
(26) Saruhan-Direskeneli G, Yentur SP, Mutlu M, Shgaiv E et al. IntrathecaloligoclonalIgG bands are infrequently found in neurobehcet’s disease. ClinExpRheumatol 2013 May- Jun 31 (3 suppl 77) : 25-7.
27- Arai Y, Kohno S, Takahashi Y, Miyajima y, Tsutusi Y. Autopsy case of neurobehcet’s disease with multifocal neutrophilic perivascular inflammation. Neuropathology 2006 ; 26 :579-85
28- Hirohata S, Suda H, Hashimoto T. Low dose weekly methotrexate for progressive neuropsychiatricmanifestations in Behcet’s disease. J NeurolScien1998 ; 159 : 187-5
29- ShunseiHirohota, HirohotzKikuci, Tetsuji Sawada, Hiroko Nagafuchiet all. Retrospective analysis of long term outcome of chronic progressive neurological manifestations in Behcet’s disease. Journal of Neurological science 349 (2015) 143-148
30-K. Hamzaoui, A. Hamzaoui, I.Gorbel ,M.Khanfir. H.Houmen. Levels of IL15 in serum and cerobrospinal fluid of patients with Behcet’s disease. Scandinavian Journal of Immunology (2006) 64, 655-660
31- K.Hamzaoui, A. Borhan-Haghighi, W. Kaabachi, A. Hamzaoui. Increased Interleukine 33 in patients with neurobehcet’sdisease : correlation with MCP-1 and IP-10 chemochines. Cellular and molecularImmunology (2014) 11, 613-616